Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis Second Quarter 2025 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 4,891,544 | $193,264,903 | +8% | 6.2% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 3,800,000 | $150,138,000 | +254% | 0.25% |
| 3. | Two Sigma Advisors John Overdeck And David Siegel | 2,667,611 | $105,397,311 | +28% | 0.22% |
| 4. | Millennium Management Israel Englander | 2,649,527 | $104,682,812 | +318% | 0.05% |
| 5. | 76,616,000 | $77,389,190 | +25% | 0.89% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.86 | 15,000 | $477,900.00 | 50,219 | 2025-05-01 | Filing | |
| $36.23 | 2,500 | $90,583.00 | 35,219 | 2024-12-23 | Filing | |
| $36.20 | 2,500 | $90,495.75 | 32,719 | 2024-12-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.63 | 400 | $17,051.00 | 86,344 | 2025-08-06 | Filing | |
| $41.87 | 4,600 | $192,595.10 | 86,744 | 2025-08-06 | Filing | |
| $42.86 | 10,000 | $428,593.00 | 89,492 | 2025-08-05 | Filing | |
| $42.80 | 9,549 | $408,701.02 | 51,507 | 2025-08-04 | Filing | |
| $45.00 | 2,432 | $109,440.00 | 179,820 | 2025-07-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 23,642,990 | $934,134,535 | 0.05% | |
| 2. | 16,714,846 | $660,403,565 | 0.01% | |
| 3. | 12,540,188 | $495,462,828 | 0.07% | |
| 4. | 10,896,937 | $430,537,983 | 0.01% | |
| 5. | 7,853,198 | $310,279,853 | 6.84% |
News See All
Ionis Pharmaceuticals (IONS) Received Positive Opinion from European Medicines Agency
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the Stocks With Huge Catalysts on the Horizon. On July 25, Ionis Pharmaceuticals, Inc.
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
Ionis Pharmaceuticals Announces Positive Donidalorsen Results for Hereditary Angioedema Published in JACI In Practice
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is one of the best mid cap pharma stocks to buy.
Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.
11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds
As per the US Bank, the healthcare in the US exhibits a large and intricate ecosystem, which is characterized by size, complexity, and influence on the broader national economy.
First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
Ionis Pharmaceuticals, Inc.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire Hedge Funds
